Skip to main content
. 2017 Jul 24;292(36):15028–15038. doi: 10.1074/jbc.M117.796284

Figure 6.

Figure 6.

Mitotic phosphorylation of Vgll4 inhibited its tumor-suppressing activity in pancreatic cancer cells. A, Vgll4 expression in pancreatic non-cancer (HPNE) and cancer cells. B, establishment of S2.013 cell lines stably expressing vector (Vec), wild-type Vgll4, Vgll4-4A, or Vgll4-4D (all are FLAG-tagged). 4A, S58A/S155A/T159A/S280A; 4D, S58D/S155D/T159D/S280D. C and D, cell migration (wound healing) assays with cell lines established in B. Data are expressed as the mean ± S.D. of at least three independent experiments. ***, p < 0.001; **, p < 0.01; *, p < 0.05 (t test). E and F, cell migration (Transwell) assays with cell lines established in B. Data are expressed as the mean ± S.D. of three independent experiments. ***, p < 0.001; *, p < 0.05 (t test). G, establishment of Tet-On-inducible cell lines expressing wild-type Vgll4 or Vgll4-4A or Vgll4-4D in BxPC3 pancreatic cancer cells. Cells were kept on Tet-approved FBS, and doxycycline was added (1 μg/ml) to the cells 2 days before the experiments. H and I, cell migration (wound healing) assays with cell lines established in G. Data are expressed as the mean ± S.D. of three independent experiments. ***, p < 0.001; **, p < 0.01 (t test).